Skip to main content
Clinical Trials/ISRCTN47673027
ISRCTN47673027Terminated未知

Minimising the risks of emergence of antibiotic resistance during therapy by precise regimen individualisation and use of combination therapy

orth Bristol NHS Trust0 sites80 target enrollmentStarted: April 26, 2022Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Terminated
Sponsor
Enrollment
80

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • 1. Intubated patients with clinician suspected Gram-negative pulmonary infection requiring antibacterial therapy
  • 2. Adults aged 18 years upwards
  • 3. Patient admitted to ICU for at least 5 days
  • 4. Patient ventilated for at least 48 hours
  • Inclusion criteria for analysis:
  • Infection with a piperacillin-tazobactam and gentamicin susceptible Gram-negative organism.

Exclusion Criteria

  • 1. Patients for whom informed consent cannot be obtained
  • 2. Allergies or intolerance to piperacillin-tazobactam or gentamicin
  • 3. Neutropaenic sepsis
  • 4. Past medical history of cystic fibrosis
  • 5. Other underlying infections pulmonary process unlikely to respond to piperacillin/tazobactam with or without gentamicin (i.e. tuberculosis, fungal pneumonia)
  • 6. Subject unlikely to survive longer than 24 hours
  • 7. Prisoners
  • 8. Pregnant women
  • 9. Non-NHS patients

Investigators

Sponsor
orth Bristol NHS Trust

Similar Trials